Perimeter Medical Imaging AI, Inc.

Ladies and gentlemen, and welcome to Perimeter Medical Q2 2026 conference call. At this time, all lines are in the listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press the star zero for the operator. This call is being recorded on Tuesday, August 18, 2026. I would now like to turn the conference over to Stephen Kilmer. With best relations, please go ahead.

Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws. These may include statements regarding the future financial position, business strategy and strategic goals, commercial activities and timing, competitive conditions, research and development activities, projected costs and capital expenditures, and Sarah Brien. Thank you for joining us today. and our public filings and press releases, which are posted on CEDARplus.ca. Our results may differ materially from those projected on today's call. No forward-looking statement can be guaranteed. Permanente takes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future, or otherwise, other than as required by law. On the call representing the company are Adrian Mendes, Perimeter's chief executive officer, Sara Brien, the company's chief financial officer, and Andrew Berkeley, Perimeter's chief innovation officer and co-founder. With that said, I'll now turn the call over to Sara.

Thanks, Steve. Good afternoon, everyone, and welcome to our second quarter of 2026 conference call. On behalf of the management team and everyone at Perimeter, I would like to thank you for your ongoing interest in our company. For those of you who are our shareholders, we appreciate your continued interest and support. Before turning the call over to Adrian to provide a commercial update, I'd like to provide a brief update on our preliminary financial results. To streamline things, all of the numbers I will refer to have been rounded, so they are approximate. Also, as a reminder, we report in U.S. dollars. Finally, as you may have noticed, these numbers are preliminary and subject to change. The reason driving this is the accounting treatment and classification of the convertible debentures that was closed in Q2 unit-based structure. While that may impact some of the expense and net loss per share figures, the accounting finalization will not change revenues or cash position. For the three-month period ending June 30th, 2026, the company recorded revenue of $503,100,000. with a full amount coming from recurring revenue, which consisted of the sale of S-Series consumables and system leases, as well as from preventative maintenance services, the sale of ESP warranty programs. This represented 31% sequential growth over Q1, 2026. Operating expenses for the three months ended June 30th, 2026 were $3.1 million. down 28% from $4.3 million in the same period in 2025. Second quarter 2026 net loss was $2.6 million or two cents per common share, a 33% improvement compared to $3.9 million or four cents per common share loss in the three months ended June 30th, 2025. Cash used in operating activities in the six months ended June 30th, 2026 was $5.1 million, a 23% year-over-year decrease from Q2 2025. As of June 30th, 2026, cash was $6.4 million. With that, I'll turn the call over to Adrian.